Search Results - "Urbaez, Kayla"

Abstract 17013: CTX320: An Investigational in vivo CRISPR-Based Therapy Efficiently and Durably Reduces Lipoprotein (a) Levels in Non-Human Primates After a Single Dose by Morrow, Phuong Khanh, D'Souza, Sanjay, Wood, Tess, Gowda, Vivek, Lee, Nicolette, Lei Zhang, Maria, Pandji, Jeremy, Serwer, Laura, Steiger, Keith, Sula, Erisa, Thorstensen, Erin, Urbaez, Kayla, Usadi, Jacob

“…Abstract only Background: Genetic and epidemiological studies have identified elevated levels of lipoprotein (a) (Lp(a)) as a direct cause of atherosclerosis…”
Get full text

Abstract 16908: CTX310: An Investigational in vivo CRISPR-Based Therapy Efficiently and Durably Reduces ANGPTL3 Protein and Triglyceride Levels in Non-Human Primates After a Single Dose by Morrow, Phuong Khanh, Chen, Yi-Shan, Serwer, Laura, Detwiler, Zachary, Flanagan, Nicole, Koch, Elizabeth, Lei Zhang, Maria, Mu, Michelle, Nguyen, Thao, Sula, Erisa, Thorstensen, Erin, Tomp, Samuel, Urbaez, Kayla, Usadi, Jacob, Wang, Li, Watrud, Kaitlin, Wood, Tess, Zhang, Xuezhi

“…Abstract only Background: Angiopoietin-like 3 (ANGPTL3) is a key regulator of lipid metabolism. In humans, naturally occurring loss-of-function variants in…”
Get full text

Abstract ND02: CTX112 and CTX131: Next-generation CRISPR/Cas9-engineered allogeneic (allo) CAR T cells incorporating novel edits that increase potency and efficacy in the treatment of lymphoid and solid tumors by Terrett, Jonathan A., Kalaitzidis, Demetrios, Dequeant, Mary-Lee, Karnik, Sushant, Ghonime, Mohammed, Guo, Changan, Chain, Robert, Heath, Heidi, Jaishankar, Nivedita, Yuen, Rachel, Settipane, Davis, Padalia, Zinkal, Zakas, Lauren, Kuppuraju, Meghna, Tetteh, Paul, Massilamany, Chandirasegaran, McEwan, Brigid, Leary, Glenn, Dar, Henia, Ferulo, Daniel, Allen, Melanie, Tipton, Kimberley, Serwer, Laura, Nguyen, Thao, Butler-Gauthier, Melanie, Sripakdeevong, Parin, Nagar, Shashwat D., Tang, Yin, Chaudhari, Hemangi, Flanagan, Nicole, Huang, Elaine, Phuyal, Shashwant, Koch, Elizabeth, Dunn, Andrew, Sula, Erisa, Waldman, Jacob, Loaiza, Cristian, Zhang, Maria Lei, Thorstensen, Erin, Steiger, Keith, Schum, Katie, Urbaez, Kayla, Benton, Mark, Ma, Anna, Cohen, Sarah, Weaver, Annie, Finch, Christopher, Morrow, Phuong Khanh

“…Abstract Allo CAR T cells represent an “off-the-shelf” treatment option that addresses the unmet need for immediately available, potentially curative…”
Get full text

274 Development of CTX112 a next generation allogeneic multiplexed CRISPR-edited CART cell therapy with disruptions of the TGFBR2 and Regnase-1 genes for improved manufacturing and potency by Kalaitzidis, Demetrios, Ghonime, Mohammed, Chain, Robert, Jaishankar, Nivedita, Settipane, Davis, Padalia, Zinkal, Zakas, Lauren, Kuppuraju, Meghna, Tetteh, Paul, Dequeant, Mary-Lee, Karnik, Sushant, Massilamany, Chandirasegaran, McEwan, Brigid, Dar, Henia, Allen, Melanie, Serwer, Laura, Nguyen, Thao, Butler-Gauthier, Melanie, Sripakdeevong, Parin, Nagar, Shashwat, Tang, Yin, Flanagan, Nicole, Huang, Elaine, Phuyal, Shashwant, Dunn, Andrew, Koch, Elizabeth, Sula, Erisa, Waldman, Jacob, Zhang, Maria Lei, Loaiza, Cristian, Thorstensen, Erin, Steiger, Keith, Schum, Katie, Urbaez, Kayla, Ma, Anna, Weaver, Annie Yang, Finch, Christopher, Cohen, Sarah, Morrow, PK, Benton, Mark, Terrett, Jonathan

“…BackgroundCTX110, a CD19-directed first-generation CRISPR-edited CAR T cell therapeutic candidate for B-cell lymphoma, has induced clinical responses and…”
Get full text